Loading
A phase 1/2 trial of Quizartinib, Fludarabine, Cytarabine and Etoposide in acute myeloid leukaemia, run by Daiichi Sankyo, active and no longer recruiting.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood is a phase 1/2 interventional study registered as NCT03793478 by Daiichi Sankyo, with 65 participants enrolled, started 2018-08-15 and due to reach its primary completion in 2027-05-01. Interventions recorded: Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis and Etoposide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Quizartinib, Daiichi Sankyo, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares FLT3-mutated acute myeloid leukaemia, Fludarabine, Cytarabine, Etoposide and the tag pipeline.
Shares Acute myeloid leukaemia in children, Fludarabine, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Cytarabine, Etoposide, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Cytarabine, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fludarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/